|Articles|September 23, 2022
Antibody-based drug discovery at the speed of light
Author(s)Curia
The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
